Duchenne Muscular Dystrophy Supportive Care Protocol

Duchenne Muscular Dystrophy (DMD) is a severe genetic muscle disease caused by mutations in the dystrophin gene on the X chromosome. It primarily affects boys, occurring in about 1 in 3,500-5,000 male births.

HOW IT WORKS:

Dystrophin is a protein that helps keep muscle cells intact. Without it, muscles are damaged with each use and gradually replaced by fat and scar tissue, leading to progressive weakness.

PROGRESSION:

•Ages 1-3: Delayed motor milestones, calf enlargement

•Ages 3-5: Difficulty running, climbing stairs, Gowers' sign

•Ages 6-12: Progressive weakness, loss of ambulation typically by age 12

•Teens: Scoliosis, respiratory decline, cardiomyopathy develops

•20s-30s: Respiratory and cardiac complications

CRITICAL: DMD requires comprehensive multidisciplinary care. This protocol is SUPPORTIVE ONLY and does not replace standard treatment.

STANDARD TREATMENTS:

•Corticosteroids (prednisone, deflazacort): Slow progression, standard of care

•Gene therapies: FDA-approved options for specific mutations (exon skipping, micro-dystrophin)

•Cardiac care: ACE inhibitors/beta-blockers for cardiomyopathy

•Respiratory care: Night-time ventilation, cough assist

•Physical/occupational therapy

•Scoliosis management

NUTRITIONAL CHALLENGES:

•Steroid side effects (weight gain, bone loss)

•Swallowing difficulties in later stages

•Constipation

•Obesity risk with reduced mobility

* Vitamin D and Calcium are CRITICAL for bone health with steroid use.

* CoQ10 and Creatine may provide some muscle support.

* Protein helps maintain muscle mass.

Expected timeline: DMD is progressive. Management focuses on maintaining function as long as possible and managing complications.

Clinical Perspective

Duchenne Muscular Dystrophy: X-linked recessive dystrophin deficiency. Incidence ~1:3500-5000 males. Caused by DMD gene mutations (deletions 60-70%, duplications, point mutations). Pathophysiology: loss of dystrophin destabilizes sarcolemma, causing muscle fiber necrosis, inflammation, fibrosis, fatty replacement. Natural history: motor delay, ambulatory until ~10-12, cardiomyopathy by teens, respiratory failure, median survival into 30s with current care.

CRITICAL: Multidisciplinary care essential. Corticosteroids remain standard of care - prolong ambulation ~2-3 years, reduce scoliosis, preserve respiratory and cardiac function. Gene therapies available for specific mutations (exondys 51, vyondys 53, amondys 45, elevidys). Cardiac management crucial - ACE inhibitors/ARBs and beta-blockers. Respiratory support extends survival significantly. Supplements are adjunctive only - bone health with steroids is primary concern.

* Vitamin D (B-grade): Bone health. Systematic review: (PMID: 28750270). 1000-2000 IU daily. Essential with steroid use.

* Calcium (B-grade): Bone health. Guidelines: (PMID: 28332116). 1000-1200mg daily.

* CoQ10 (C-grade): Mitochondrial function. Review: (PMID: 24268541). 100-200mg daily.

* Creatine (C-grade): Muscle energy. Cochrane: (PMID: 12679790). 5g daily. Some evidence for modest strength benefits.

* Omega-3 (C-grade): Anti-inflammatory. Review: (PMID: 27840029). 1-2g EPA+DHA daily.

* Carnitine (C-grade): Energy metabolism. Review: (PMID: 23597877). 1-2g daily.

* Protein (C-grade): Muscle maintenance. Guidelines: (PMID: 28332116). 1-1.2g/kg/day.

* Taurine (C-grade): Membrane stabilizer. Review: (PMID: 28241238). 1-3g daily.

Assessment targets: 6MWT, timed function tests, FVC, cardiac echo/MRI, DEXA, nutritional status.

Protocol notes: Steroids: deflazacort may have less weight gain than prednisone; dosing ~0.9mg/kg/day deflazacort or 0.75mg/kg/day prednisone. Gene therapy: exon skipping (eteplirsen, golodirsen, casimersen) for amenable mutations; micro-dystrophin (delandistrogene moxeparvovec) approved 2023. Bone health: DEXA monitoring; bisphosphonates if osteoporosis. Cardiac: start ACE-I/ARB by age 10 or when cardiomyopathy detected; add beta-blocker as needed. Respiratory: annual FVC; introduce BiPAP when FVC <50%; cough assist important. Scoliosis: surgical fixation may be needed; timing important. Contractures: stretching, bracing, rarely surgical release. Diet: caloric restriction often needed to prevent obesity; avoid excess sodium. Constipation: common; fiber, fluids, stool softeners. Transition: pediatric to adult care planning. Carrier testing: important for family members. Psychological support: essential for patient and family. Clinical trials: encourage participation when appropriate.

View All Protocols